ASLAN Pharmaceuticals announces receipt of Nasdaq notice

seekingalpha04-20

ASLAN Pharmaceuticals (NASDAQ:ASLN) on Friday announced that it received a letter on April 18 from Nasdaq informing that it failed to maintain the continued listing requirement under certain Nasdaq ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428694596?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-20 05:19","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2428694596","market":"nz","top_or_hot":-1,"title":"ASLAN Pharmaceuticals announces receipt of Nasdaq notice","media":"seekingalpha","content":"<div>\n<p>ASLAN Pharmaceuticals (NASDAQ:ASLN) on Friday announced that it received a letter on April 18 from Nasdaq informing that it failed to maintain the continued listing requirement under certain Nasdaq ...</p>\n\n<a href=\"https://seekingalpha.com/news/4091677-aslan-pharmaceuticals-announces-receipt-of-nasdaq-notice\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASLAN Pharmaceuticals announces receipt of Nasdaq notice</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASLAN Pharmaceuticals announces receipt of Nasdaq notice\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-20 05:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4091677-aslan-pharmaceuticals-announces-receipt-of-nasdaq-notice><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ASLAN Pharmaceuticals (NASDAQ:ASLN) on Friday announced that it received a letter on April 18 from Nasdaq informing that it failed to maintain the continued listing requirement under certain Nasdaq ...</p>\n\n<a href=\"https://seekingalpha.com/news/4091677-aslan-pharmaceuticals-announces-receipt-of-nasdaq-notice\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSQ","symbol_name":"纳指反向ETF","start_time":0,"source_url":"https://seekingalpha.com/news/4091677-aslan-pharmaceuticals-announces-receipt-of-nasdaq-notice","article_id":"2428694596","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428694596","pubTimestamp":1713561572,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"ASLAN Pharmaceuticals  on Friday announced that it received a letter on April 18 from Nasdaq informing that it failed to maintain the continued listing requirement under certain Nasdaq listing rules. The company has a period of 45 calendar days, or until June 3, to submit a plan to regain compliance with the stockholders’ equity requirement.  If such a plan is submitted and accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the letter for the company to regain compliance. Source: Press Release    More on ASLAN Pharmaceuticals  ASLAN Pharmaceuticals announces $5M registered direct offering Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical earnings data for ASLAN Pharmaceuticals Financial information for ASLAN Pharmaceuticals","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSQ":"纳指反向ETF","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","QLD":"纳指两倍做多ETF","QQQ":"纳指100ETF","BK4535":"淡马锡持仓","TQQQ":"纳指三倍做多ETF","BK4588":"碎股","SQQQ":"纳指三倍做空ETF","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","QID":"纳指两倍做空ETF",".IXIC":"NASDAQ Composite","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","ASLN":"ASLAN PHARMACEUTICALS LIMITED SPON ADS EACH REP 25 ORD SHS (P/S)","BK4139":"生物科技"},"translate_title":"阿斯兰制药宣布收到纳斯达克通知","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASLN":1,".IXIC":1,"NQmain":1,"NDAQ":1,"TQQQ":0.6,"SQQQ":0.6,"QQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"MNQmain":0.6},"content_text":"ASLAN Pharmaceuticals (NASDAQ:ASLN) on Friday announced that it received a letter on April 18 from Nasdaq informing that it failed to maintain the continued listing requirement under certain Nasdaq listing rules. The company has a period of 45 calendar days, or until June 3, to submit a plan to regain compliance with the stockholders’ equity requirement.  If such a plan is submitted and accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the letter for the company to regain compliance. Source: Press Release    More on ASLAN Pharmaceuticals  ASLAN Pharmaceuticals announces $5M registered direct offering Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical earnings data for ASLAN Pharmaceuticals Financial information for ASLAN Pharmaceuticals","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428694596"}